title: Effect of extended-release niacin on cardiovascular events and kidney function in chronic kidney disease: a post hoc analysis of the AIM-HIGH trial.
abstract: Chronic kidney disease (CKD) in patients is strongly associated with cardiovascular morbidity and mortality, and prevalent abnormal lipid metabolism. The AIM-HIGH trial examined the benefits of adding extended-release niacin (ERN) to simvastatin in patients with established coronary heart disease. Here we conducted a post hoc analysis of the AIM-HIGH trial examining whether participants derived cardiovascular or renal benefits when stratified by renal function. Of 3414 participants, 505 had stage 3 CKD at baseline. Among the CKD subset, demographics and cardiovascular disease (CVD) risk factors were well balanced in the ERN and placebo arms. Compared with placebo, CKD participants receiving ERN had a significant decrease in triglycerides by a median of 59.0 mg/dl, and high-density lipoprotein cholesterol significantly increased by a mean of 11.3 mg/dl over a mean follow-up of 3 years. CVD events were similar between CKD participants in both arms. However, all-cause mortality was significantly higher in the ERN group (hazard ratio of 1.73). Mean change in eGFR among ERN-treated CKD participants was not significantly different between study arms. Thus, among AIM-HIGH participants with CKD, the addition of ERN to simvastatin for secondary prevention of CVD improved triglyceride and high-density lipoprotein-cholesterol concentrations but did not improve cardiovascular outcomes or kidney function, and was associated with higher all-cause mortality.
authors: Division of Nephrology, Department of Medicine, Carver College of Medicine, University of Iowa Hospitals and Clinics, Iowa City, Iowa, USA.
authors: Roberto S
authors: RS
authors: Kalil
authors: Divisions of Nephrology and Cardiology, Department of Medicine, Albany Medical College and Samuel Stratton VA Medical Center, Albany, New York, USA.
authors: Jeffrey H
authors: JH
authors: Wang
authors: Division of Nephrology, Department of Medicine, University of Washington, Seattle, Washington, USA.
authors: Ian H
authors: IH
authors: de Boer
authors: Divisions of Nephrology and Cardiology, Department of Medicine, Albany Medical College and Samuel Stratton VA Medical Center, Albany, New York, USA.
authors: Roy O
authors: RO
authors: Mathew
authors: Division of Nephrology, Department of Medicine, University of California San Diego, La Jolla, California, USA.
authors: Joachim H
authors: JH
authors: Ix
authors: Divisions of Nephrology and Cardiology, Department of Medicine, Albany Medical College and Samuel Stratton VA Medical Center, Albany, New York, USA.
authors: Arif
authors: A
authors: Asif
authors: Axio Research, LLC. Seattle, Washington, USA.
authors: Xuefeng
authors: X
authors: Shi
authors: Divisions of Nephrology and Cardiology, Department of Medicine, Albany Medical College and Samuel Stratton VA Medical Center, Albany, New York, USA.
authors: William E
authors: WE
authors: Boden
mesh_terms: D000368:Aged; D002318:Cardiovascular Diseases / Q000097:blood / Q000401:mortality / Q000517:prevention & control*; D002423:Cause of Death; D008076:Cholesterol, HDL / Q000097:blood; D003692:Delayed-Action Preparations; D004359:Drug Therapy, Combination / Q000009:adverse effects; D005260:Female; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009525:Niacin / Q000627:therapeutic use*; D051436:Renal Insufficiency, Chronic / Q000401:mortality / Q000503:physiopathology*; D055502:Secondary Prevention / Q000379:methods; D019821:Simvastatin / Q000627:therapeutic use; D014280:Triglycerides / Q000097:blood
chemical_list: D008076:Cholesterol, HDL; D003692:Delayed-Action Preparations; D000960:Hypolipidemic Agents; D014280:Triglycerides; D009525:Niacin; D019821:Simvastatin
references: N Engl J Med. 2014 Jul 17;371(3):203-12
references: 25014686
references: Clin J Am Soc Nephrol. 2007 Nov;2(6):1131-9
references: 17942759
references: Kidney Int Suppl (2011). 2013 Jan;3(1):19-62
references: 25018975
references: JAMA. 2011 Jun 15;305(23):2432-9
references: 21673295
references: Kidney Int. 2004 Sep;66(3):1123-30
references: 15327407
references: N Engl J Med. 2012 Nov 29;367(22):2089-99
references: 23126252
references: N Engl J Med. 2007 Nov 22;357(21):2109-22
references: 17984165
references: Kidney Int. 2003 Jan;63(1):179-85
references: 12472781
references: Diabetes Care. 2012 Feb;35(2):218-25
references: 22210576
references: Curr Opin Nephrol Hypertens. 2003 Nov;12(6):593-8
references: 14564195
references: Ann Intern Med. 2009 May 5;150(9):604-12
references: 19414839
references: Am J Physiol Renal Physiol. 2009 Jul;297(1):F106-13
references: 19420110
references: Lancet. 2011 Jun 25;377(9784):2181-92
references: 21663949
references: Circulation. 2001 Nov 27;104(22):2673-8
references: 11723017
references: Am J Physiol Renal Physiol. 2006 Feb;290(2):F262-72
references: 16403839
references: J Am Coll Cardiol. 2008 Apr 15;51(15):1448-54
references: 18402899
references: Clin Chem Lab Med. 2004;42(12):1355-63
references: 15576296
references: N Engl J Med. 2004 Sep 23;351(13):1296-305
references: 15385656
references: Am J Kidney Dis. 2006 Jan;47(1):42-50
references: 16377384
references: N Engl J Med. 2011 Dec 15;365(24):2255-67
references: 22085343
references: J Am Coll Cardiol. 2013 Oct 22;62(17):1580-4
references: 23916935
references: Am Heart J. 2011 Mar;161(3):538-43
references: 21392609
references: JAMA. 2012 Mar 28;307(12):1302-9
references: 22453571
references: Atherosclerosis. 2009 May;204(1):216-21
references: 18822413
references: Lancet. 2010 Nov 13;376(9753):1670-81
references: 21067804
references: Clin Nephrol. 2012 Jul;78(1):1-9
references: 22732331